Sparks commentary

Healthcare

Sparks

Biomea Fusion’s (NASDAQ: BMEA) BMF-219 trials continue
Published by Arron Aatkar

Biomea Fusion announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials, COVALENT-111 and COVALENT-112, for BMF-219, which is being evaluated as a potential new treatment for type 2 and type 1 diabetes, respectively. BMF-219 is Biomea Fusion’s lead asset and it has potential as a first-in-class agent for the treatment of diabetes, operating by a novel covalent mechanism of action. Top-line data readouts for COVALENT-111 and COVALENT-112 remain on track for Q424.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free